Oncology Institute (TOI) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.
- Oncology Institute's Income towards Parent Company fell 242.66% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.3 million, marking a year-over-year increase of 563.11%. This contributed to the annual value of -$64.7 million for FY2024, which is 2215.65% up from last year.
- Per Oncology Institute's latest filing, its Income towards Parent Company stood at -$16.5 million for Q3 2025, which was down 242.66% from -$17.0 million recorded in Q2 2025.
- In the past 5 years, Oncology Institute's Income towards Parent Company ranged from a high of $19.3 million in Q1 2022 and a low of -$30.0 million during Q1 2023
- For the 5-year period, Oncology Institute's Income towards Parent Company averaged around -$11.1 million, with its median value being -$15.5 million (2024).
- As far as peak fluctuations go, Oncology Institute's Income towards Parent Company soared by 203634.54% in 2022, and later plummeted by 55142.11% in 2023.
- Over the past 5 years, Oncology Institute's Income towards Parent Company (Quarter) stood at -$10.2 million in 2021, then decreased by 8.38% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then rose by 29.71% to -$13.2 million in 2024, then fell by 25.2% to -$16.5 million in 2025.
- Its Income towards Parent Company stands at -$16.5 million for Q3 2025, versus -$17.0 million for Q2 2025 and -$19.6 million for Q1 2025.